|
Explanatory variables
|
Sub-categories
|
Mean (SD)
|
Median [Q1–Q3]
|
[Min–max]
|
|---|
|
Study design
|
SR/MA
|
14.9 (37.0)
|
3.5 [1.0–10.0]
|
[0.0–268.0]
|
|
RCT
|
20.7 (50.5)
|
3.0 [0.0–16.0]
|
[0.0–428.0]
|
|
Phase I/II, non-RCT
|
6.5 (17.2)
|
2.0 [0.0–4.0]
|
[0.0–139.0]
|
|
Observational study
|
13.4 (39.7)
|
2.0 [0.0–7.0]
|
[0.0–319.0]
|
|
Abstract conclusion
|
In favour of study treatment
|
16.6 (44.8)
|
2.0 [0.0–9.0]
|
[0.0–428.0]
|
|
Not in favour of study treatment
|
11.5 (32.5)
|
2.0 [0.0–7.0]
|
[0.0–319.0]
|
|
Funding source
|
Profit
|
13.9 (41.1)
|
2.0 [0.0–9.0]
|
[0.0–370.0]
|
|
Non-profit
|
15.4 (41.1)
|
2.0 [0.0–8.0]
|
[0.0–428.0]
|
|
Open access
|
Yes
|
17.9 (49.3)
|
3.0 [1.0–8.0]
|
[0.0–428.0]
|
|
No
|
10.6 (24.8)
|
1.5 [0.0–8.0]
|
[0.0–258.0]
|
|
Press release
|
Yes
|
118.6 (87.5)
|
84.5 [58.0–144.5]
|
[29.0–428.0]
|
|
No
|
7.0 (19.0)
|
2.0 [0.0–5.0]
|
[0.0–268.0]
|
-
SR/MA systematic review/meta-analysis, RCT randomized controlled trial
